REMARKS

The above amendments have been made to place this divisional application in proper form for examination.

Claims 22 and 23, which were restricted out of Parent Application No. 09/402,229, have been added. Claim 22 is supported by the last third of page 15. New claim 23 is supported by lines 4 to 22 of page 15. Values for the variables have been inserted from claim 1 as originally filed.

The remaining claims, claims 1-21 have been canceled.

It is noted that the application is a copy of the International application (PCT/EP98/02257) as published (WO 98/49166), with amended pages 1, 1A, 6, 56, 145, 146, 147 and 148 which were amended during the International phase. A copy of the cover sheet from WO 98/49166 has also been included since it contains the original Abstract.

Claims to priority

U. S. priority is claimed under 35 USC §120 to parent application 09/402,229, filed September 29, 1999.

Foreign priority is claimed under 35 USC §119 and/or §365(b) to PCT/EP98/02257, filed April 10, 1998.

Foreign priority is claimed under 35 USC §120 to GB 9708406.5, filed April 25, 1997, to GB 9715380.3, filed July 22, 1997, and to GB 9722954.6, filed October 30, 1997.

An early and favorable action is respectfully requested.

Respectfully submitted,

Date: Mancis 23, 2004

James T. Jones

Attorney for Applicant(s)

Reg. No. 30,561

Pfizer Inc. Patent Department, Box 8260-1611 Eastern Point Road Groton, CT 06340 (860) 441-4903